Autonomix Medical Inc. logo

Autonomix Medical Inc. (AMIX)

Market Open
12 Jun, 13:51
NASDAQ (CM) NASDAQ (CM)
$
0. 37
-0.02
-5.9897%
$
2.09M Market Cap
- P/E Ratio
- Div Yield
15,338 Volume
0 Eps
$ 0.39
Previous Close
Investors:
Add Transaction
Day Range
0.37 0.4
Year Range
0.2 2.64
Want to track AMIX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

AMIX trading today lower at $0.37, a decrease of -5.9897% from yesterday's close, completing a monthly increase of 7.5588% or $0.03. Over the past 12 months, AMIX stock lost -32.2527%.
AMIX is not paying dividends to its shareholders.
The last earnings report, released on Jun 04, 2026, exceeded the consensus estimates by 0.26%. On average, the company has surpassed earnings expectations by 0.12%, based on the last three reports.
Autonomix Medical Inc. has completed 1 stock splits, with the recent split occurring on Oct 25, 2024.
The company's stock is traded on one exchange.

AMIX Chart

People also search for

Estrella Immunopharma Inc.
$ 1.05
-2.3148%
Kalaris Therapeutics, Inc.
$ 9.81
+4.1401%
PolyPid Ltd.
$ 4.6
+0.6565%
Lantern Pharma Inc.
$ 3.94
-3.0713%
Eloxx Pharmaceuticals, Inc.
$ 14.6
+15.4866%
Autonomix Medical, Inc. (AMIX) Upgraded to Strong Buy: Here's Why

Autonomix Medical, Inc. (AMIX) Upgraded to Strong Buy: Here's Why

Autonomix Medical, Inc. (AMIX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 10 months ago
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech

AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech

Autonomix Medical, Inc.  AMIX recently announced that it has been granted a key U.S. patent for its innovative catheter-based platform designed to sense and differentiate nerve signals in real-time. This technology represents a significant leap forward in the field of neuromodulation, with the potential to enhance treatment precision across a wide range of chronic conditions, including cancer and pain management.

Zacks | 1 year ago
AMIS Stock Surges After RF Ablation Trial Unveils Positive Results

AMIS Stock Surges After RF Ablation Trial Unveils Positive Results

Autonomix's RF ablation trial for pancreatic cancer pain shows early success, enabling significant pain relief and opioid elimination in responding patients.

Zacks | 1 year ago

Autonomix Medical Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
BD
Brian Dechow SWAN Capital LLC
10 $38 $3.8 -$34.2 -90%

Autonomix Medical Inc. (AMIX) FAQ

What is the stock price today?

The current price is $0.37.

On which exchange is it traded?

Autonomix Medical Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is AMIX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 2.09M.

Has Autonomix Medical Inc. ever had a stock split?

Autonomix Medical Inc. had 1 splits and the recent split was on Oct 25, 2024.

Autonomix Medical Inc. Profile

Health Care Technology Industry
Healthcare Sector
Bradley Hauser CEO
NASDAQ (CM) Exchange
05330T106 CUSIP
US Country
5 Employees
- Last Dividend
25 Oct 2024 Last Split
9 Dec 2005 IPO Date

Overview

Globe Metals & Mining Limited operates in the resource sector with a strong focus on exploring, developing, and investing in various projects, primarily within Australia and Africa. Its main area of interest lies in the exploration and potential development of niobium and tantalum deposits, essential elements used in various high-tech and critical applications. The company, initially known as Globe Uranium Limited, was established in 2005 and has since redirected its focus towards niobium and tantalum, marking a significant pivot in its strategic operations. Globe Metals & Mining is strategically headquartered in West Perth, Australia, positioning itself within a hub of mining and exploration activities and expertise. This strategic placement affords the company access to a wealth of resources and industry knowledge, enhancing its operations and expansion capabilities. Furthermore, Globe Metals & Mining serves as a subsidiary under Apollo Metals Investment Co., Limited, indicating a level of financial backing and operational support that could enrich its exploration and developmental pursuits. The Kanyika project in Malawi stands as its flagship venture, where the company holds a 100% interest, underlining its commitment to exploring and potentially mining niobium and tantalum on a significant scale.

Products and Services

Globe Metals & Mining Limited's exploration and development activities center around two critical minerals:

  • Niobium: An element primarily used to produce high-strength, low-alloy steel. This material is crucial for construction, automotive, and pipeline industries due to its ability to enhance strength, resistance to corrosion, and weldability. Globe Metals & Mining's endeavors in locating and potentially extracting niobium could significantly impact these industries by ensuring the supply of this valuable resource.
  • Tantalum: This element is vital for the electronics industry, used in the manufacture of tantalum capacitors found in computers, mobile phones, and other electronic devices. Tantalum's importance lies in its ability to store and release electrical charge, facilitating the performance and miniaturization of electronic products. Globe Metals & Mining's focus on tantalum exploration signifies its potential contribution to the tech industry by securing a stable supply of this essential component.

Contact Information

Address: 21 Waterway Avenue
Phone: 713 588 6150